ORGANIZATION

Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs

By Takashi Ebisawa January 19, 2024

Ishikawa Pharmaceutical Association President Keiji Nakamori
Ishikawa Pharmaceutical Association President Keiji Nakamori

The Ishikawa Pharmaceutical Association on January 18 urged Health Minister Keizo Takemi that emergency measures be taken to lift the shipment restrictions of certain medicines within the quake-hit prefecture.

Keiji Nakamori, president of the association, met Mr Takemi in Kanazawa to directly make this request as the minister visited the Ishikawa capital in the aftermath of the massive earthquake on New Year’s Day.

Mr Nakamori told Jiho that he made the plea in order to secure the necessary drugs in areas affected by the disaster. In response, Mr Takemi instructed officials accompanying him to convey this request to the ministry headquarters, according to Mr Nakamori.

An association of drug distributors in Ishikawa Prefecture and the Federation of Japan Pharmaceutical Wholesalers Association (JPWA) on January 9 had made a joint request to the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) to prioritize supplies of products under shipment controls and other necessary medicines to the Hokuriku central Japan area. However, the shortage in medicines has not yet been resolved for pharmacists dispensing drugs at the frontline, including Mr Nakamori himself.

Also, as secondary evacuations progress, from the most affected areas to Kanazawa and other regions, the shortage of drugs is becoming an issue for not only the hardest-hit zones but the whole of the prefecture. The Ishikawa Pharmaceutical Association thus asked the minister for the execution of bolder measures.

Speaking to Jiho, Mr Nakamori emphasized, “Wholesalers are making requests to manufacturers, but the situation has not changed at all between before and after the earthquake.”

Mr Nakamori also told the minister that the pharmacy outlets he runs have reported that they are currently not seeing deliveries for 10 medicines, including the expectorant carbocysteine, antipyretic analgesic Calonal (acetaminophen), and montelukast, a treatment for bronchial asthma and allergic rhinitis.

Related Article

ORGANIZATION

By Sakura Kono

Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…

By Philip Carrigan

As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…

By Takashi Ebisawa

A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…